<DOC>
	<DOC>NCT01053520</DOC>
	<brief_summary>This is a Phase 1, randomized, open-label, single center, three period crossover study to determine the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 12 healthy female subjects will be enrolled in this study.</brief_summary>
	<brief_title>Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects</brief_title>
	<detailed_description>This is a Phase 1, randomized, open-label, single center, three period crossover study to determine the oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 12 healthy female subjects will be enrolled in this study.</detailed_description>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>Female and age is between 18 and 55 years, inclusive. Must be surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), postmenopausal (for at least 2 years), or practicing at least one acceptable method of birth control. Must have negative results for pregnancy tests performed at Screening on a urine sample obtained within 28 days prior to initial study drug administration, and on Period 1 Day 1 on a serum specimen. Body Mass Index (BMI) is 18 to 29, inclusive. BMI is calculated as weight in kg divided by the square of height measured in meters. Must have adequate bone marrow function per local laboratory reference range (Platelets &gt;/= lower limit of normal range, ANC &gt;/= lower limit of normal range) A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12lead electrocardiogram (ECG). Must voluntarily sign and date each informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any studyspecific procedures. History of significant sensitivity to any drug History of drug or alcohol abuse w/i 6 months or currently receiving Disulfiram Known/suspected history of HIV History of or active medical condition(s) or surgical procedure(s) that might affect GI motility, pH, absorption History of thrombocytopenic associated bleeding w/i 1 year prior to ABT263 Significant history of cardiovascular disease (e.g., MI, thrombotic or thromboembolic event in last 6 months), renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, respiratory (except mild asthma), gastrointestinal, hematologic, or hepatic disease or diabetes, cancer, epilepsy, or seizures that in the opinion of the PI would adversely affect her participating in the study. Underlying condition predisposing to bleeding or currently exhibits signs of clinically significant bleeding or active peptic ulcer disease or other hemorrhagic esophagitis/gastritis. Positive result for drugs of abuse, alcohol, cotinine, hepatitis A virus immunoglobulin M (HAVIgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab). Consumed alcohol, grapefruit or starfruit product, or Seville oranges w/i 3 days prior to ABT263 Received aspirin, anticoagulation therapy, or any drugs or herbal supplements that affect platelet function w/i 7 days prior to/during ABT263 Used any medications, vitamins, or herbal supplements (except contraceptives) w/i 14 days prior to ABT263 Received any drug by injection or biologic agent w/i 30 days prior to ABT263 (except parenteral hormonal contraceptives) Used known inhibitors or inducers CYP3A w/i 1 month prior to ABT263; Received any investigational product w/i 6 weeks prior to ABT263 Used tobacco or nicotineproducts w/i 6 months prior to ABT263 Pregnant or breastfeeding Donation or loss of &gt;/=550 mL blood or received transfusion of blood product w/i 8 weeks prior ABT263 Currently enrolled in another study. The PI decides the subject is unsuitable to receive ABT263.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>